The Industry That Cannot Buy Customers: What a Name Is Worth When Google Won't Sell You Ads

Google will not sell a cannabis company a search ad. Neither will Meta. Not for a higher bid, not with better creative, not at any price. Strip paid acquisition out of an industry and the remaining questions get very old-fashioned very quickly: who has heard of you, and can they find you again?

Potency figures from the peer-reviewed PLOS ONE study cited below. Market size estimates vary by source; see sources.

The constraintAn industry that cannot buy customers

Google prohibits paid cannabis advertising under its Dangerous Products and Services policy — Search, Display, YouTube and Shopping alike. The exceptions are so narrow they prove the rule: topical hemp-derived CBD under 0.3% THC, LegitScript certification required, and permitted in California, Colorado and Puerto Rico only. Google opened its first cannabis advertising pilot anywhere in the world in Canada in August 2025, Search only, federally licensed Canadian operators only.

Meta bans cannabis advertising on Facebook and Instagram outright. CBD requires prior written authorisation plus LegitScript certification.

Every playbook a normal B2B company runs on is therefore unavailable. There is no cost-per-click to optimise, no lookalike audience, no retargeting pool, no paid brand-defence campaign on your own name. A competitor with ten times your marketing budget cannot outspend you, because there is nothing to spend it on.

When nobody can buy attention, attention goes to whoever is easiest to remember and hardest to confuse with someone else.

The productWhat a testing laboratory actually sells

Steep Hill opened the first commercial cannabis laboratory in the United States in 2007, founded by David Lampach, Addison DeMoura and Steve DeAngelo. The origin is instructive: Harborside had approached conventional analytical labs and could not find one willing to test cannabis for the consumer market. Steep Hill began with a single gas chromatograph and the job of inventing the potency and microbiological methods the sector now takes for granted.

A testing lab does not sell chemistry. Every accredited lab in a given state runs broadly comparable instruments to broadly comparable standards. What it sells is belief in a number — a cultivator's willingness to put that number on a label, a regulator's willingness to accept it, and a consumer's willingness to pay more for a higher one.

That is an unusual product, because it is destroyed instantly by any doubt about the seller's independence. And independence here is not a marketing position. It is a licensing condition: state programmes require testing by independent, state-licensed laboratories, commonly accredited to ISO/IEC 17025, and generally prohibit financial ties between a lab and the businesses whose products it tests.

The problemAnd that belief is publicly in trouble

A peer-reviewed study published in PLOS ONE tested retail cannabis flower against its label claims. Average measured THC potency came in 23.1% below the lowest label figure and 35.6% below the highest. Roughly 70% of samples were more than 15% below what the label said.

The mechanism has a name in the trade: lab shopping. Producers move samples between laboratories until they get the potency number they want, and MJBizDaily's analysis of licensed testing-lab data across four states found the inflation routine and systematic, in some cases exceeding 25%. The pressure runs downhill onto the labs, which risk losing accounts to whichever competitor is most accommodating.

So: an industry that cannot advertise, selling a product made entirely of credibility, inside a sector whose credibility is measurably compromised and publicly reported on. Every structural force in that description pushes value toward the one thing a lab can own outright and a competitor cannot imitate — how it presents itself.

The mechanismWhy the name carries more weight here than elsewhere

The last row matters more than it looks. Because licences are public, this is a category where a buyer can be reached by name and reputation alone. Trade press, conferences, regulator relationships and word of mouth inside a small licensed community are the whole funnel — and all four of those channels are spoken, not clicked. They reward a name that survives being said aloud at a booth and typed correctly the following week.

Market realityWhat these names have actually sold for

Here is the part most brokers leave out. Descriptive cannabis domains have not historically commanded brandable-tier prices. Across a study of the 130 largest reported cannabis domain sales, the pattern is consistent:

Around 60% of the sales in that study closed under $10,000. Anyone pricing a descriptive cannabis name against Kush.com is pricing against the wrong comparable.

There is a reasonable argument that those comps underprice the advertising ban — most were struck before the current platform position hardened, and a name in a category with no paid channel is doing work a name in an advertisable category never has to do. That is an argument, not a proof, and we would rather state it as one. The verifiable position is simpler: the comparable sales are modest, and a buyer should negotiate knowing them.

The listingWho CannabisLabs.com is actually for

CannabisLabs.com was registered in 2009 and names the category exactly. Four buyer types have a real use for it:

1. A licensed testing laboratory or multi-state lab networkThe direct case. Independence is the entire proposition, and a category-exact name is the cheapest available way to look like the reference standard rather than one of eight licensees in a state.
2. A laboratory equipment or consumables distributorSelling chromatographs, columns and reference materials into every lab in the sector — a name that reads as the category's address rather than one vendor's.
3. A compliance software or LIMS vendorLaboratory information management systems are already sold as the answer to lab shopping and chain-of-custody integrity.
4. A trade publisher or industry data providerTesting results, potency data and lab performance are exactly the kind of information a sector this contested pays to have aggregated.

Honest limitsWhat this name does not do

It does not confer accreditation, licensure or independence — those are earned from regulators, and no domain substitutes for ISO/IEC 17025 or a state licence. It does not carry traffic history, rankings or a customer list. It will not rank on its own for the queries a cultivator types; that is still won with content, data and reputation.

The sale is the domain name only — no logo, no brand identity. BuyURLs.com does not perform trademark clearance, and nothing here is legal advice; any buyer building a brand on a name should have counsel run clearance for their specific services and territory first. Cannabis is also a state-by-state regulatory patchwork and remains federally controlled in the United States; a buyer's own compliance position is theirs to establish.

Figures are as reported by the sources above and were current at publication; market-size estimates differ materially between research firms and we have cited the lower of those we found. This article is general information, not legal, regulatory or investment advice. BuyURLs.com sells domain names; it does not perform trademark clearance, and buyers are responsible for their own. Domain valuation is not an exact science, and past sales are not a forecast of any particular outcome.